Skip to main content
Erschienen in:

08.08.2017 | Case Report

Achievement of the longest survival of paraneoplastic pemphigus with bronchiolitis obliterans associated with follicular lymphoma using R-CHOP chemotherapy

verfasst von: Shin Lee, Takahiro Yamauchi, Norito Ishii, Takashi Hashimoto, Keiichi Kinoshita, Shin Imamura, Kenichi Kamiya

Erschienen in: International Journal of Hematology | Ausgabe 6/2017

Einloggen, um Zugang zu erhalten

Abstract

Paraneoplastic pemphigus (PNP) is a rare, fatal, paraneoplastic autoimmune mucocutaneous blistering disease, commonly associated with lymphoproliferative disorders, including malignant lymphomas. Lymphoproliferative disorders associated with PNP are sometimes associated with a serious lung complication, bronchiolitis obliterans (BO). Due to its rarity, guidelines for the management of PNP have not been established. Furthermore, most patients die within 1 year. Here we report the successful treatment of lymphoma-associated PNP and BO using R-CHOP chemotherapy. A 53-year-old Japanese man was admitted to our hospital for severe erosive stomatitis. Computed tomography and positron emission tomography showed multiple lymphadenopathies. He was diagnosed with follicular lymphoma (Ann Arbor stage IVA) and PNP-related BO. The patient underwent six cycles of R-CHOP and an additional cycle of rituximab. Both the erosive stomatitis and the obstructive lung disease persisted, but complete response of the follicular lymphoma was achieved. The patient survived 27 months after diagnosis. Although he died from progressive respiratory failure due to BO, we note that this patient achieved the longest survival of any reported case of PNP-related BO associated with a lymphoproliferative disorder. The present case suggests that intensive immunochemotherapy for underlying lymphoma may improve the prognosis in patients with PNP-related BO associated with lymphoma.
Literatur
1.
Zurück zum Zitat Anhalt GJ, Kim SC, Stanley JR, Korman NJ, Jabs DA, Kory M, et al. Paraneoplastic pemphigus. An autoimmune mucocutaneous disease associated with neoplasia. N Engl J Med. 1990;323:1729–35.CrossRefPubMed Anhalt GJ, Kim SC, Stanley JR, Korman NJ, Jabs DA, Kory M, et al. Paraneoplastic pemphigus. An autoimmune mucocutaneous disease associated with neoplasia. N Engl J Med. 1990;323:1729–35.CrossRefPubMed
2.
Zurück zum Zitat Nguyen VT, Ndoye A, Bassler KD, Shults LD, Shields MC, Ruben BS, et al. Classification, clinical manifestations, and immunopathological mechanisms of the epithelial variant of paraneoplastic autoimmune multiorgan syndrome: a reappraisal of paraneoplastic pemphigus. Arch Dermatol. 2001;137:193–206.PubMed Nguyen VT, Ndoye A, Bassler KD, Shults LD, Shields MC, Ruben BS, et al. Classification, clinical manifestations, and immunopathological mechanisms of the epithelial variant of paraneoplastic autoimmune multiorgan syndrome: a reappraisal of paraneoplastic pemphigus. Arch Dermatol. 2001;137:193–206.PubMed
3.
Zurück zum Zitat Oursler JR, Labib RS, Ariss-Abdo L, Burke T, O’keefe EJ, Anhalt GJ, et al. Human autoantibodies against desmoplakins in paraneoplastic pemphigus. J Clin Investig. 1992;89:1775–82.CrossRefPubMedPubMedCentral Oursler JR, Labib RS, Ariss-Abdo L, Burke T, O’keefe EJ, Anhalt GJ, et al. Human autoantibodies against desmoplakins in paraneoplastic pemphigus. J Clin Investig. 1992;89:1775–82.CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Hashimoto T, Amagai M, Watanabe K, Chorzelski TP, Black MM, Stevens HP, et al. Characterization of paraneoplastic pemphigus autoantigens by immunoblot analysis. J Investig Dermatol. 1995;104:829–34.CrossRefPubMed Hashimoto T, Amagai M, Watanabe K, Chorzelski TP, Black MM, Stevens HP, et al. Characterization of paraneoplastic pemphigus autoantigens by immunoblot analysis. J Investig Dermatol. 1995;104:829–34.CrossRefPubMed
5.
Zurück zum Zitat Frew JW, Murrell DF. Current management strategies in paraneoplastic pemphigus (paraneoplastic autoimmune multiorgan syndrome). Dermatol Clin. 2011;29:419–25.CrossRefPubMed Frew JW, Murrell DF. Current management strategies in paraneoplastic pemphigus (paraneoplastic autoimmune multiorgan syndrome). Dermatol Clin. 2011;29:419–25.CrossRefPubMed
6.
Zurück zum Zitat Leger S, Picard D, Ingen-Housz-Oro S, Arnault JP, Aubin F, Carsuzaa F, et al. Prognostic factors of paraneoplastic pemphigus. Arch Dermatol. 2012;148:1165–72.CrossRefPubMed Leger S, Picard D, Ingen-Housz-Oro S, Arnault JP, Aubin F, Carsuzaa F, et al. Prognostic factors of paraneoplastic pemphigus. Arch Dermatol. 2012;148:1165–72.CrossRefPubMed
7.
Zurück zum Zitat Animesh A. Paraneoplastic pemphigus: autoimmune-cancer nexus in the skin. Anticancer Agents Med Chem. 2015;15:1215–23.CrossRef Animesh A. Paraneoplastic pemphigus: autoimmune-cancer nexus in the skin. Anticancer Agents Med Chem. 2015;15:1215–23.CrossRef
8.
Zurück zum Zitat Sehgal VN, Srivastava G. Paraneoplastic pemphigus/paraneoplastic autoimmune multiorgan syndrome. Int J Dermatol. 2009;48:162–9.CrossRefPubMed Sehgal VN, Srivastava G. Paraneoplastic pemphigus/paraneoplastic autoimmune multiorgan syndrome. Int J Dermatol. 2009;48:162–9.CrossRefPubMed
9.
Zurück zum Zitat Nousari HC, Deterding R, Wojtczack H, Aho S, Uitto J, Hashimoto T, et al. The mechanism of respiratory failure in paraneoplastic pemphigus. N Engl J Med. 1999;340:1406–10.CrossRefPubMed Nousari HC, Deterding R, Wojtczack H, Aho S, Uitto J, Hashimoto T, et al. The mechanism of respiratory failure in paraneoplastic pemphigus. N Engl J Med. 1999;340:1406–10.CrossRefPubMed
10.
Zurück zum Zitat Maldonado F, Pittelkow MR, Ryu JH. Constrictive bronchiolitis associated with paraneoplastic autoimmune multi-organ syndrome. Respirology. 2009;14:129–33.CrossRefPubMed Maldonado F, Pittelkow MR, Ryu JH. Constrictive bronchiolitis associated with paraneoplastic autoimmune multi-organ syndrome. Respirology. 2009;14:129–33.CrossRefPubMed
11.
Zurück zum Zitat Nikolskaia OV, Nousari CH, Anhalt GJ. Paraneoplastic pemphigus in association with Castleman’s disease. Br J Dermatol. 2003;149:1143–51.CrossRefPubMed Nikolskaia OV, Nousari CH, Anhalt GJ. Paraneoplastic pemphigus in association with Castleman’s disease. Br J Dermatol. 2003;149:1143–51.CrossRefPubMed
12.
Zurück zum Zitat Joly P, Richard C, Gilbert D, Couville P, Chosidow O, Roujeau JC, et al. Sensitivity and specificity of clinical, histologic, and immunologic features in the diagnosis of paraneoplastic pemphigus. J Am Acad Dermatol. 2000;43:619–26.CrossRefPubMed Joly P, Richard C, Gilbert D, Couville P, Chosidow O, Roujeau JC, et al. Sensitivity and specificity of clinical, histologic, and immunologic features in the diagnosis of paraneoplastic pemphigus. J Am Acad Dermatol. 2000;43:619–26.CrossRefPubMed
13.
Zurück zum Zitat Meyer KC, Raghu G, Verleden GM, Corris PA, Aurora P, Wilson KC, et al. An international ISHLT/ATS/ERS clinical practice guideline: diagnosis and management of bronchiolitis obliterans syndrome. Eur Respir J. 2014;44:1479–503.CrossRefPubMed Meyer KC, Raghu G, Verleden GM, Corris PA, Aurora P, Wilson KC, et al. An international ISHLT/ATS/ERS clinical practice guideline: diagnosis and management of bronchiolitis obliterans syndrome. Eur Respir J. 2014;44:1479–503.CrossRefPubMed
14.
Zurück zum Zitat Anderson KM, Smith P, Norton A, Hancock BW, Hoskin PJ, MacLennan KA, et al. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomized controlled trial. Lancet. 2003;362:516–22.CrossRef Anderson KM, Smith P, Norton A, Hancock BW, Hoskin PJ, MacLennan KA, et al. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomized controlled trial. Lancet. 2003;362:516–22.CrossRef
15.
Zurück zum Zitat Brice P, Bastion Y, Lepage E, Brousse N, Haioun C, Moreau P, et al. Comparison in low-tomor-burden follicular lymphoma between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Group d’Etude des Lymphomes Folliculares. J Clin Oncol. 1997;15:1110–7.CrossRefPubMed Brice P, Bastion Y, Lepage E, Brousse N, Haioun C, Moreau P, et al. Comparison in low-tomor-burden follicular lymphoma between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Group d’Etude des Lymphomes Folliculares. J Clin Oncol. 1997;15:1110–7.CrossRefPubMed
16.
Zurück zum Zitat Solal-Celigny P, Lepage E, Brousse N, Tendler CL, Brice P, Haioun C, et al. Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas: final analysis of survival and toxicity in the Group d’Etude des Lymphomes Folliculares 86 trial. J Clin Oncol. 1998;16:2332–8.CrossRefPubMed Solal-Celigny P, Lepage E, Brousse N, Tendler CL, Brice P, Haioun C, et al. Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas: final analysis of survival and toxicity in the Group d’Etude des Lymphomes Folliculares 86 trial. J Clin Oncol. 1998;16:2332–8.CrossRefPubMed
17.
Zurück zum Zitat Ohzono A, Sogame R, Li X, Teye K, Tsuchiasaka A, Numata S, et al. Clinical immunological findings in 104 cases of paraneoplastic pemphigus. Br J Dermatol. 2015;173:1447–52.CrossRefPubMed Ohzono A, Sogame R, Li X, Teye K, Tsuchiasaka A, Numata S, et al. Clinical immunological findings in 104 cases of paraneoplastic pemphigus. Br J Dermatol. 2015;173:1447–52.CrossRefPubMed
18.
Zurück zum Zitat Kaplan I, Hodak E, Ackerman L, Mimouni D, Calderon S. Neoplasms associated with paraneoplastic pemphigus: a review with emphasis on non-hematologic malignancy and oral mucosal manifestations. Oral Oncol. 2004;40:553–62.CrossRefPubMed Kaplan I, Hodak E, Ackerman L, Mimouni D, Calderon S. Neoplasms associated with paraneoplastic pemphigus: a review with emphasis on non-hematologic malignancy and oral mucosal manifestations. Oral Oncol. 2004;40:553–62.CrossRefPubMed
19.
Zurück zum Zitat Hirano T, Higuchi Y, Yuki H, Hirata S, Nosaka K, Ishii N, et al. Rituximab monotherapy and rituximab-containing chemotherapy were effective for paraneoplastic pemphigus accompanying follicular lymphoma, but not for subsequent bronchiolitis obliterans. J Clin Exp Hematol. 2015;55:83–8.CrossRef Hirano T, Higuchi Y, Yuki H, Hirata S, Nosaka K, Ishii N, et al. Rituximab monotherapy and rituximab-containing chemotherapy were effective for paraneoplastic pemphigus accompanying follicular lymphoma, but not for subsequent bronchiolitis obliterans. J Clin Exp Hematol. 2015;55:83–8.CrossRef
20.
Zurück zum Zitat Hoffman MA, Qiao X, Anhalt GJ. CD8+ T lymphocytes in bronchiolitis obliterans, paraneoplastic pemphigus, and solitary Castleman’s disease. N Engl J Med. 2003;349:407–8.CrossRefPubMed Hoffman MA, Qiao X, Anhalt GJ. CD8+ T lymphocytes in bronchiolitis obliterans, paraneoplastic pemphigus, and solitary Castleman’s disease. N Engl J Med. 2003;349:407–8.CrossRefPubMed
21.
Zurück zum Zitat Chang JM, Lee HJ, Goo JM, Lee HY, Lee JJ, Chung JK, et al. False positive and false negative FDG-PET scans in various thoracic diseases. Korean J Radiol. 2006;7:57–9.CrossRefPubMedPubMedCentral Chang JM, Lee HJ, Goo JM, Lee HY, Lee JJ, Chung JK, et al. False positive and false negative FDG-PET scans in various thoracic diseases. Korean J Radiol. 2006;7:57–9.CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Estenne M, Hertz MI. Bronchiolitis obliterans after human lung transplantation. Am J Respir Crit Care. 2002;16:440–4.CrossRef Estenne M, Hertz MI. Bronchiolitis obliterans after human lung transplantation. Am J Respir Crit Care. 2002;16:440–4.CrossRef
23.
Zurück zum Zitat Tateishi U, Hasegawa T, Terauchi T, Moriyama N, Arai Y. Disease activity and 18F-FDG uptake in organizing pneumonia: semi-quantitative evaluation using computed tomography and position emission tomography. Eur J Nucl Med Mol Imaging. 2006;33:906–12.CrossRefPubMed Tateishi U, Hasegawa T, Terauchi T, Moriyama N, Arai Y. Disease activity and 18F-FDG uptake in organizing pneumonia: semi-quantitative evaluation using computed tomography and position emission tomography. Eur J Nucl Med Mol Imaging. 2006;33:906–12.CrossRefPubMed
24.
Zurück zum Zitat Takahashi M, Shimatsu Y, Kazama T, Kimura K, Otuka T, Hashimoto T, et al. Paraneoplastic pemphigus associated with bronchiolitis obliterans. Chest. 2000;117:603–7.CrossRefPubMed Takahashi M, Shimatsu Y, Kazama T, Kimura K, Otuka T, Hashimoto T, et al. Paraneoplastic pemphigus associated with bronchiolitis obliterans. Chest. 2000;117:603–7.CrossRefPubMed
25.
Zurück zum Zitat Gudi VS, Ormerod AD, Weir J, Kerr KM, Devereux G. Severe breathlessness, mouth ulcers and skin blistering in a female. Eur Respir J. 2004;24:884–7.CrossRefPubMed Gudi VS, Ormerod AD, Weir J, Kerr KM, Devereux G. Severe breathlessness, mouth ulcers and skin blistering in a female. Eur Respir J. 2004;24:884–7.CrossRefPubMed
26.
Zurück zum Zitat Wang SH, Chu CY, Chen HH, Chang YL, Chen KY, Chiu HC, et al. Paraneoplastic pemphigus and bronchiolitis obliterans in a patient with splenic B-cell lymphoma. J Formos Med Assoc. 2007;106:768–73.CrossRefPubMed Wang SH, Chu CY, Chen HH, Chang YL, Chen KY, Chiu HC, et al. Paraneoplastic pemphigus and bronchiolitis obliterans in a patient with splenic B-cell lymphoma. J Formos Med Assoc. 2007;106:768–73.CrossRefPubMed
27.
Zurück zum Zitat Park KY, Choi SY, Seo SJ, Hong CK. Case or paraneoplastic pemphigus associated with retroperitoneal diffuse large B-cell lymphoma and fetal bronchiolitis obliterans-like lung disease. J Dermatol. 2013;40:142–4.CrossRef Park KY, Choi SY, Seo SJ, Hong CK. Case or paraneoplastic pemphigus associated with retroperitoneal diffuse large B-cell lymphoma and fetal bronchiolitis obliterans-like lung disease. J Dermatol. 2013;40:142–4.CrossRef
28.
Zurück zum Zitat Kanaoka M, Matsukura S, Ishikawa H, Matsuura M, Ishii N, Hashimoto T, et al. Paraneoplastic pemphigus associated with fetal bronchiolitis obliterans and appearance of anti-BP180 antibodies in the late stage of the disease. J Dermatol. 2014;41:628–30.CrossRefPubMed Kanaoka M, Matsukura S, Ishikawa H, Matsuura M, Ishii N, Hashimoto T, et al. Paraneoplastic pemphigus associated with fetal bronchiolitis obliterans and appearance of anti-BP180 antibodies in the late stage of the disease. J Dermatol. 2014;41:628–30.CrossRefPubMed
29.
Zurück zum Zitat Morikawa K, Tsuji T, Yamasaka H, Egashira S, Kaguchi A, Kido M, et al. Paraneoplastic pemphigus occurs most commonly in indolent B call lymphoma. Acta Haematol. 2014;132:73–4.CrossRefPubMed Morikawa K, Tsuji T, Yamasaka H, Egashira S, Kaguchi A, Kido M, et al. Paraneoplastic pemphigus occurs most commonly in indolent B call lymphoma. Acta Haematol. 2014;132:73–4.CrossRefPubMed
Metadaten
Titel
Achievement of the longest survival of paraneoplastic pemphigus with bronchiolitis obliterans associated with follicular lymphoma using R-CHOP chemotherapy
verfasst von
Shin Lee
Takahiro Yamauchi
Norito Ishii
Takashi Hashimoto
Keiichi Kinoshita
Shin Imamura
Kenichi Kamiya
Publikationsdatum
08.08.2017
Verlag
Springer Japan
Erschienen in
International Journal of Hematology / Ausgabe 6/2017
Print ISSN: 0925-5710
Elektronische ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-017-2305-2

Neu im Fachgebiet Onkologie

Duale Checkpointhemmung gegen Melanome verlängert langfristig das Leben

Im Vergleich zu den Überlebenschancen vor der Einführung von Immuncheckpointhemmern (ICI) ist der Fortschritt durch eine ICI-Kombination mit unterschiedlichen Tagets bei fortgeschrittenem Melanom erstaunlich. Das belegen die finalen Ergebnisse der CheckMate-067-Studie und geben Betroffenen "Hoffnung auf Heilung".

Knochenmarktransplantat als Chance für ältere AML-Patienten

Lange Zeit ist die Transplantation von hämatopoetischen Stammzellen nur bei jüngeren Patienten mit akuter myeloischer Leukämie praktiziert worden. Inzwischen profitieren auch Ältere davon. Ergebnisse einer Studie unterstützen dieses Vorgehen.

Nierenzellkarzinom: Kein Nachteil durch subkutan appliziertes Nivolumab

Die subkutane Applikation von Nivolumab ist nach Daten einer Phase-3-Studie ähnlich gut wirksam wie die intravenöse: Die Pharmakokinetik ist vergleichbar, die objektive Response war in der Studie sogar leicht besser als in der Gruppe mit Infusionen.

Vorteile für Androgenentzug plus Androgenrezeptorblockade

Für Männer mit metastasiertem hormonsensitivem Prostata-Ca. (mHSPC), die keine Hormonchemotherapie wollen oder vertragen, ist der Androgenentzug plus Darolutamid eine Alternative: Das Progressionsrisiko wird im Vergleich zum alleinigen Androgenentzug fast halbiert.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.